Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Mineralys Therapeutics Inc’s stock clocked out at $40.74, down -5.52% from its previous closing price of $43.12. In other words, the price has decreased by -$5.52 from its previous closing price. On the day, 1.54 million shares were traded. MLYS stock price reached its highest trading level at $43.52 during the session, while it also had its lowest trading level at $40.59.
Ratios:
To gain a deeper understanding of MLYS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.50 and its Current Ratio is at 25.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15. On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30. On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when Slingsby Brian Taylor sold 1,000,000 shares for $43.35 per share. The transaction valued at 43,350,000 led to the insider holds 7,903,838 shares of the business.
Catalys Pacific Fund, LP bought 1,000,000 shares of MLYS for $42,120,000 on Nov 20 ’25. On Nov 11 ’25, another insider, Levy Adam Scott, who serves as the CFO and Secretary of the company, sold 119,524 shares for $44.88 each. As a result, the insider received 5,363,716 and left with 19,396 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 3224161792 and an Enterprise Value of 2630533888.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.40, which has changed by 2.3504274 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $47.65, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -0.96%, while the 200-Day Moving Average is calculated to be 82.77%.
Shares Statistics:
It appears that MLYS traded 1.93M shares on average per day over the past three months and 1983080 shares per day over the past ten days. A total of 78.97M shares are outstanding, with a floating share count of 56.37M. Insiders hold about 28.77% of the company’s shares, while institutions hold 79.32% stake in the company. Shares short for MLYS as of 1763078400 were 6889251 with a Short Ratio of 3.57, compared to 1760486400 on 7132486. Therefore, it implies a Short% of Shares Outstanding of 6889251 and a Short% of Float of 10.89.
Earnings Estimates
The dynamic stock of Mineralys Therapeutics Inc (MLYS) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.44 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$2.13 and -$2.81 for the fiscal current year, implying an average EPS of -$2.41. EPS for the following year is -$2.48, with 6.0 analysts recommending between -$1.74 and -$3.43.
